NCT00530062View on ClinicalTrials.gov

Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

July 25, 2007

Primary Completion Date

October 24, 2008

Study Completion Date

October 24, 2008

Conditions
Asthma
Interventions
DRUG

Albuterol-HFA-MDI

Inhalation Aerosols, 90 mcg, 1 dose per treatment period

DRUG

Albuterol-HFA-BAI

Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.

Trial Locations (5)

55402

Clinical Study Site, Minneapolis

73120

Clinical Study Site, Oklahoma City

80401

Teva Clinical Study Site, Lakewood

92647

Clinical Study Site, Huntington Beach

97035

Clinical Study Site, Lake Oswego

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT00530062 - Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma | Biotech Hunter | Biotech Hunter